Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review

Masaaki Hotta, Tomoki Ito, Akiko Konishi, Hideaki Yoshimura, Takahisa Nakanishi, Shinya Fujita, Atsushi Satake and Shosaku Nomura

Abstract:
Few reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe a 45-year-old woman who had MM (diagnosed with IgA-κ type) with CNS relapse early after undergoing autologous hematopoietic stem cell transplantation. Because no standard treatment for CNS lesions of MM has been established, we conducted a literature review on the cerebrospinal fluid (CSF) transferability of drugs for MM, since it was considered to be a useful tool for CNS involvement. Immunomodulatory-drugs including pomalidomide exhibit a good CSF transfer ability, and, therefore, may be beneficial against the CNS involvement of MM.

Key words: multiple myeloma, central nervous system, pomalidomide, intrathecal chemotherapy, craniospinal radiation

(Intern Med 60: 463-468, 2021)
(DOI: 10.2169/internalmedicine.5646-20)

Introduction

Previous studies have shown that the multiple myeloma (MM) genome is complex, and that MM patients have extremely diverse cytogenetic abnormalities with genomic heterogeneity (1). Thus, MM demonstrates a highly variable clinical course. Few reports have so far described neurologic complications arising from direct MM cell involvement in the central nervous system (CNS) (2-6). We herein present a case of an MM patient with an early relapse localized in the CNS early after autologous hematopoietic stem cell transplantation (ASCT). Because no standard treatment for CNS lesions of MM has yet been established (5, 7) due to a lack of evidence, we conducted a literature review on the cerebrospinal fluid (CSF) transferability of drugs for MM. The current case demonstrates that such a presentation of MM can be successfully treated with pomalidomide-dexamethasone (Pd) therapy together with whole-brain and craniospinal irradiation and intrathecal chemotherapy.

Case Report

A 45-year-old woman with M-proteinemia, anemia, and hypercalcemia was referred to our hospital. The patient had initially noticed general pain and consulted her physician. Other than her performance status being affected by general pain, the general and neurologic examination was unremarkable. A blood examination showed anemia, hypercalcemia, and elevated lactate dehydrogenase (LDH), and IgA-κ type M protein was detected by serum protein immunoelectrophoresis (Table 1). Bone marrow (BM) specimens revealed 25.7% of atypical plasma cells with the expression of CD38, CD56, and CD138, but no expression of CD19, CD20, MPC-1, CD45, or CD49e, which was compatible with a diagnosis of MM. Chromosome and fluorescence in situ hybridization cytogenetic examinations of the BM showed complicated karyotypes, 72% IgH/FGFR3 fusion and 72% deletion 13q signal-positive cells, but no deletion of either 17p or IgH/MAF fusion. Diffusion-weighted whole-body imag-
ing with background body signal suppression (DWIBS) detected diffuse abnormal signals in BM including in many vertebrae. From these findings, MM was diagnosed according to the Revised-International Staging System III (8).

Treatment with bortezomib-dexamethasone (Bd) therapy (1.3 mg/m² bortezomib twice a week and 40 mg dexamethasone per week) was started, but it proved to be ineffective. The addition of lenalidomide administered [25 mg/day (on days 1-21)] with Bd transiently decreased the IgA levels. However, 1 week after the addition of lenalidomide, the right femoral diaphysis became fractured, and surgery was thus performed. After surgery, carfilzomib-lenalidomide-dexamethasone (CLd) therapy [with at a dose and schedule according to the ASPIRE protocol (9)] was started. After three courses of CLd therapy, a stringent complete response (sCR) was achieved. High-dose melphalan (200 mg/m²) therapy with ASCT was performed at 9 months after the initial diagnosis, and then the patient maintained an sCR after ASCT, which was confirmed by a BM biopsy and DWIBS. Lenalidomide maintenance therapy (10 mg orally) was then started. Approximately 2 months after ASCT, severe headache, nausea, and vomiting suddenly appeared, and the patient was hospitalized. A CSF examination revealed a marked increase in the total cell count (441/μL), completely consisting of abnormal plasma cells (Fig. 1A), and increased total protein (61 mg/dL) and decreased sugar levels (26 mg/dL). An examination of the plasma cell clonality of the CSF consisting of abnormal plasma cells (Fig. 1A), and increased total protein (61 mg/dL) and decreased sugar levels (26 mg/dL). An examination of the plasma cell clonality of the CSF showed expression of CD38, CD56, and CD138 but not CD19, CD20, MPC-1, CD45 or CD49e (Fig. 1B), which was the same result found for the MM cells in BM at diagnosis. Bacterial culture, a tuberculosis PCR test, and viral gene PCR tests including herpes virus were all negative. Although no lesions could be detected by head computed tomography, magnetic resonance imaging (MRI) revealed patchy hyperintense regions on T2-weighted images (Fig. 2). These findings were indicative of MM involvement in the CNS. Blood examinations showed no anemia, renal dysfunction, or hypercalcemia. M-protein was not detected by serum protein immunoelectrophoresis. No abnormal increase in the plasma cells was observed, and no cells with IgH/FGFR3 fusion or a deletion of 13q signals were detected in BM specimens. No systemic lesions were detected on DWIBS. These findings indicate that the relapse was localized to the CNS.

Dexamethasone monotherapy was started, and the intrathecal injection of methotrexate (15 mg), cytarabine (40 mg), and dexamethasone (4 mg) was performed twice a week, four times in total. Thereafter, Pd therapy with 3 mg pomalidomide and 40 mg dexamethasone [performed on a schedule according to the MM-003 protocol (10)] with whole-brain/craniospinal irradiation (27 Gy/15 fr) was started. The number of myeloma cells in the CSF rapidly decreased, and the cells were observed to have disappeared at the end of irradiation. However, Pd therapy was transiently discontinued 10 days later because of myelosuppression and then was again resumed and continued after the completion of whole-brain/spinal irradiation. Thereafter, no further relapse was observed (Fig. 3).

Three months later, DWIBS revealed a mass lesion around the right kidney, which was indicative of extramedullary recurrence, but no relapse of the CNS lesions. Three courses of daratumumab-lenalidomide-dexamethasone therapy [with a dose and schedule according to the POLLUX protocol (11)] were performed, but no reductive effect on the abdominal tumor was observed. Thereafter, conventional chemotherapy [PACE (cisplatin, 10 mg/m²/day; doxorubicin, 10 mg/m²/day; cyclophosphamide, 400 mg/m²/day; and etoposide, 40 mg/m²/day from days 1 to 4)] was temporarily effective, but the tumor recurred, and the patient eventually died 12 months after the onset of CNS relapse (21 months after the diagnosis of MM). After the onset of the abdominal lesion, no relapse of the CNS lesions was observed.
Figure 1. Cerebrospinal fluid specimens showing a marked increase in the total cell count (441/μL), completely consisting of abnormal plasma cells. A: May-Giemsa staining ×400 and ×20 original magnification. B: A flow cytometric analysis of CD38-positive CSF cells. CSF: cerebrospinal fluid, SSC: side scatter

Figure 2. Magnetic resonance imaging showing patchy hyperintense on T2-weighted images.
In MM, extramedullary lesions emerge in approximately 6-8% of cases at the time of diagnosis and in approximately 10-30% of cases in the advanced or relapse stage (12, 13), but the frequency of CNS involvement is only approximately 1% (2-6). The clinical symptoms of CNS involvement in MM are diverse and uncharacteristic, including headache, nausea, vomiting, consciousness disorder, limb weakness, and convulsions (14). Because these symptoms are similar to those of hypercalcemia, uremia, and hyperviscosity syndrome or side effects caused by chemotherapy, a CSF examination to confirm the presence of MM cells in CSF is crucial for making an accurate diagnosis (14). Moreover, the detection of abnormal free light chain in the CSF can provide significant evidence (15), even if myeloma cells are absent in the CSF. MRI may show high-intensity portions of the meninges and formation of solid tumors in the brain.

Although it is difficult to predict the CNS involvement of MM, features of CNS involvement include high-risk chromosomal abnormalities, high LDH levels, high β2 microglobulin levels, extramedullary lesions, and leukemic change (4, 5). In particular, a high frequency of chromosomal deletion 17p or deletion 13q has been reported (16, 17).

The median age at the time of the initial diagnosis of MM patients, who develop CNS involvement during the clinical course, is 54-64 years (2-6), which is relatively younger than the age of onset of MM, as was seen in our case. The early onset of MM may be an important indicator of CNS involvement. Abdallah et al. reported that 42.9% of patients develop CNS involvement during the progression stage of relapsed MM, 48.6% of patients in the stable stage during treatment, and 8.6% of patients in the remission state (14). The average latency period from MM diagnosis to diagnosis of CNS involvement is 15 months, and the latency is 32.1 months in patients with ASCT, which is longer than that in patients without ASCT (8.3 months) (14). Our patient had a younger age, an aggressive disease course with resistance to bortezomib, and high-risk chromosomal abnormalities, thus suggesting a poor prognosis. Indeed, the latent period of between MM diagnosis and onset of CNS relapse was 11 months, which is very short. Furthermore, two months after ASCT, the tumor recurred only in the CNS despite hematologic remission. Thus, if unexplained neurological findings occur at any time during the disease course in patients with risk factors for CNS involvement, then either MRI or a CSF examination should be promptly performed for verification.

Although newly developed therapeutic agents have improved the prognosis of MM, no standard treatment for CNS involvement has yet been established, and the prognosis is
very poor, with a median overall survival (OS) of less than 3–6 months (2–6). According to our literature review on CSF transfer of drugs for MM, immunomodulatory drugs (IMiDs) have CSF transferability (Table 2). Cases of successful treatment with thalidomide or lenalidomide have been reported (3, 18-20). Thalidomide can be detected in CSF after an oral administration (18, 21, 22), and lenalidomide can cross the blood-brain barrier (BBB) (19, 20, 23). In particular, reports have shown that pomalidomide has good CSF transferability (24-26) and activity in extramedullary disease (27). In addition, Chen et al. reported that six of nine long-term survivors (median OS of 17.1 months) with CNS involvement received IMiDs-based therapy combined with intrathecal chemotherapy plus irradiation and/or systemic chemotherapy (28). Intrathecal chemotherapy is often effective against various hematological malignancies and CNS involvement of MM (15). Although a rapid therapeutic effect can be obtained, a long-term therapeutic effect of intrathecal chemotherapy is difficult to maintain. Thus, this therapy should be used as a bridge for subsequent systemic therapy. Moreover, MM cells are highly radiosensitive (29); thus, radiotherapy is also effective for CNS involvement and it is also more effective when combined with chemotherapy (3). In the present case, because of recurrence after CLd and lenalidomide maintenance therapy, pomalidomide was used instead of lenalidomide treatment. Because there was no recurrence in the CNS, combination therapy with pomalidomide, radiotherapy, and intrathecal chemotherapy was considered to be effective in our patient.

One case report showed the inefficacy of bortezomib therapy for CNS involvement of MM because of its poor CSF transferability (30). In general, proteasome inhibitors such as carfilzomib and ixazomib have a good ability to permeate throughout the body tissues but cannot penetrate BBB (Table 2); thus, there are no data on the efficacy of carfilzomib and ixazomib for CNS lesions. However, the use of bortezomib has been reported to enhance radiosensitivity and chemosensitivity (31), and studies of CNS lesion treatment with combination therapy including bortezomib should be conducted in the future. To our knowledge, one report examined the CSF transferability of daratumumab (32), and two case reports described significant activity of daratumumab for CNS lesions of MM when concomitantly used with intrathecal chemotherapy (33, 34). There are no current data of CSF transferability and the effectiveness of isatuximab and elotuzumab for CNS lesions.

It is possible that the induction of CLd followed by high-dose melphalan chemotherapy of ASCT might have insufficient CNS effects, because proteasome inhibitors carfilzomib has less CNS transferability and alkylating agents such as cyclophosphamide or melphalan can poorly penetrate the CSF (6). We speculated that the initial clones of MM in our case may have escaped into and grown locally in the CNS, where the drugs had not sufficiently penetrated, thus resulting in a local early relapse.

**Conclusion**

CNS involvement, as seen in our case, is an important consideration for patients with a younger disease onset and risk factors such as chromosomal abnormalities which predict a poor prognosis and high LDH levels. Regardless of hematological remission, when CNS symptoms develop, it is necessary to actively search for CNS lesions by a CSF examination and head MRI. MM patients with CNS lesions have a poor prognosis, but IMiDs such as pomalidomide may be effective because of their CSF transferability; thus, it may be beneficial to administer combination therapies including IMiDs, radiotherapy, and intrathecal chemotherapy against MM with CNS involvement. Crucial data are still sparse regarding treatment, and the accumulation of data from more cases is important to verify the choice of combination drugs for CNS lesions of MM.

**Author’s disclosure of potential Conflicts of Interest (COI),**

Tomoki Ito: Honoraria, Celgene, Bristol-Myers Squibb and Takeda.

**Acknowledgement**

We thank Lisa Kreiner, PhD, for editing a draft of this manuscript.

**References**

1. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implica-

---

**Table 2. Data of CSF Transferability and Efficacy of MM Drugs.**

| Drugs | CSF transferability | Cases for CNS involvement of MM |
|-------|---------------------|---------------------------------|
| **IMiDs** | | |
| Thalidomide | good<sup>19, 23</sup> | effective<sup>18, 21, 22, 28</sup> |
| Lenalidomide | good<sup>19, 23</sup> | effective<sup>19, 20, 28</sup> |
| Pomalidomide | good<sup>44</sup> | effective<sup>25, 26</sup> |
| **Proteasome inhibitors** | | |
| Bortezomib | poor<sup>30</sup> | ineffective<sup>30</sup> |
| Carfilzomib | poor* | no data |
| Ixazomib | poor* | no data |
| **Antibody-drugs** | | |
| Daratumumab | good<sup>22</sup> | effective<sup>32, 33, 34</sup> |
| Isatuximab | no data | no data |
| Elotuzumab | no data | no data |

*no experimental data exist.
1. Nieuwenhuizen L, Biesma DH. Central nervous system myelomato-
xis: review of the literature. Eur J Haematol 80: 1-9, 2008.
2. Gozzetti A, Cerase A, Lotfi F, et al. Extramedullary intracranial lo-
calization of multiple myeloma and treatment with novel agents: a
retrospective survey of 50 patients. Cancer 118: 1574-1584, 2012.
3. Katodritou E, Terpos E, Kastritis E, et al. Lack of survival im-
provement with novel anti-myeloma agents for patients with multi-
ple myeloma and central nervous system involvement: the Greek
Myeloma Study Group experience. Ann Hematol 94: 2033-2042,
2015.
4. Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. Characteri-
cization of central nervous system multiple myeloma in the era
of novel therapies. Leuk Lymphoma 57: 1709-1713, 2016.
5. Nahu H, Svedmyr E, Lerner R. Bendamustine in combination with
high-dose radiotherapy and thalidomide is effective in treatment of
multiple myeloma with central nervous system involvement. Eur J
Hematol 92: 454-455, 2014.
6. Touzeau C, Moreau P. How I treat extramedullary myeloma.
Blood 127: 971-976, 2016.
7. Miguel JS, Weikel K, Moreau P, et al. Pomalidomide plus low-
dose dexamethasone versus high-dose dexamethasone alone for
patients with relapsed and refractory multiple myeloma (MM-003):
a randomised, open-label, phase 3 trial. Lancet Oncol 14: 1055-
1066, 2013.
8. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide,
and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:
142-152, 2015.
9. Lee J, Kek M, Demopoulos AM. The successful treatment of a
recurrent intracranial, dural-based plasmacytoma with lenalido-
mide. J Neurooncol 19: 217-220, 2014.
10. Malidomide. Leuk Lymphoma 54: 864-866, 2013.
11. Muscal JA, Sun Y, Nuchterng JG, et al. Plasma and cerebrospinal
fluid pharmacokinetics of thalidomide and lenalidomide in nonhu-
man primates. Cancer Chemother Pharmacol 95: 943-947, 2012.
12. Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant
therapeutic activity against CNS lymphoma with a major impact
on the tumor microenvironment in murine models. PLoS One 8:
e71754, 2013.
13. Lelen X, Karlin L, Macro M, et al. Pomalidomide plus low-dose
dexamethasone in multiple myeloma with deletion 17p and/or
translocation (4;14): IFM 2010-02 trial results. Blood 125:
1411-1417, 2015.
14. Mussetti A, Dhalo S, Montefusco V. Effective treatment of po-
malidomide in central nervous system myelomatosis. Leuk Lym-
phoma 54: 864-866, 2013.
15. Quach H, Ryan G, Ganju V, Prince HM. Effective treatment of
leptomeningeal multiple myeloma with total craniospinal irradi-
ation supported by second allogeneic donor stem cell infusion.
Bone Marrow Transplant 5: 423-424, 2005.
16. Mele G, Pinna S, Alloro E, Brocca MC, Coppi MR, Quarta G. In-
efficacy of bortezomib therapy for CNS involvement of refractory
multiple myeloma. Leukemia 25: 906-908, 2011.
17. Chen CI, Masih-Khan E, Jiang H, et al. Long-term survival with
central nervous system involvement: long term survival can be
achieved with radiation, intrathecal chemotherapy, and immuno-
modulatory agents. Br J Haematol 162: 483-488, 2013.
18. Elhassadi E, Murphy M, Hacking D, Farrell M. Durable treat-
ment response of relapsing CNS plasmacytoma using intrathecal che-
motherapy, radiotherapy, and Daratumumab. Clin Case Rep 6:
723-728, 2018.
19. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radio-
sensitivity by proteasome inhibition: implications for a role of NF-
kappaB. Int J Radiat Oncol Biol Phys 50: 183-191, 2001.
20. Vercruyssen M, El Hachem G, Maerevoet M. The Daratumumab
crosses the blood brain barrier. Clin Lymphoma Myeloma Leuk 18:
S289, 2018.
21. Elhassadi E, Murphy M, Hacking D, Farrell M. Durable treatment
response of relapsing CNS plasmacytoma using intrathecal chemo-
therapy, radiotherapy, and Daratumumab. Clin Case Rep 6:
723-728, 2018.
22. Vercruyssen M, El Hachem G, Maerevoet M. The Daratumumab
crosses the blood brain barrier. Clin Lymphoma Myeloma Leuk 18:
S289, 2018.
23. Elhassadi E, Murphy M, Hacking D, Farrell M. Durable treatment
response of relapsing CNS plasmacytoma using intrathecal che-
motherapy, radiotherapy, and Daratumumab. Clin Case Rep 6:
723-728, 2018.
24. Vercruyssen M, El Hachem G, Maerevoet M. The Daratumumab
crosses the blood brain barrier. Clin Lymphoma Myeloma Leuk 18:
S289, 2018.
25. Elhassadi E, Murphy M, Hacking D, Farrell M. Durable treatment
response of relapsing CNS plasmacytoma using intrathecal chemo-
therapy, radiotherapy, and Daratumumab. Clin Case Rep 6:
723-728, 2018.
26. Vercruyssen M, El Hachem G, Maerevoet M. The Daratumumab
crosses the blood brain barrier. Clin Lymphoma Myeloma Leuk 18:
S289, 2018.